Zhang Xin, Pan Jiangxiao, Xu Runnan, Fu Yijia, Lv Bodong
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Hangzhou Jiuyao Medical Beauty Clinic, Hangzhou, China.
Transl Androl Urol. 2024 Nov 30;13(11):2625-2643. doi: 10.21037/tau-24-514. Epub 2024 Nov 28.
The treatment of prostate cancer (PCa) often comes with the risk of erectile dysfunction (ED). As therapeutic technologies continue to advance, the incidence of ED and its treatment methods are also evolving. This paper aimed to provide a comprehensive analysis of the latest developments in PCa treatment, with a particular focus on its relationship with ED, and to review current innovative strategies for ED treatment.
This study conducted a literature search in databases including PubMed, Excerpta Medica, Web of Science, Scopus, and the Cochrane Library, using keywords including "prostate cancer", "active surveillance", "radiation therapy", "cryotherapy", "radical prostatectomy", "immunotherapy", "chemotherapy", "androgen deprivation therapy", "erectile dysfunction", and "therapeutic advances", to collect English-language literature published from 1966 to June 2024.
Active surveillance (AS) strategies have significantly reduced the incidence of ED. Technological advancements such as radiation therapy (RT), precise delineation techniques, and improvements in cryotherapy equipment are all dedicated to reducing the risk of ED. Intraoperative nerve monitoring combined with robot-assisted radical prostatectomy (RP) plays a key role in protecting the cavernous nerves and improving postoperative erectile function (EF) recovery. The impact of immunotherapy and chemotherapy on the risk of ED still needs to be clarified with additional clinical data. Androgen deprivation therapy (ADT) is often carried out as part of a combined treatment or through novel administration modalities to reduce its side effects. Given the limitations of traditional ED treatment methods, emerging treatments such as physical energy therapy, stem cell and platelet-rich plasma (PRP) therapy, gene and targeted therapies, tissue engineering and nerve transplantation, and traditional Chinese medicine (TCM) represent novel solutions for ED treatment.
With the innovation of PCa treatment technologies, the incidence of ED has declined, and emerging ED treatment methods have benefited the recovery of sexual function in patients with PCa. These advances may form the basis from which further innovations in PCa treatment strategies can be developed.
前列腺癌(PCa)的治疗常常伴随着勃起功能障碍(ED)的风险。随着治疗技术不断进步,ED的发生率及其治疗方法也在不断演变。本文旨在全面分析PCa治疗的最新进展,特别关注其与ED的关系,并综述当前ED治疗的创新策略。
本研究在包括PubMed、医学文摘数据库(Excerpta Medica)、科学引文索引(Web of Science)、Scopus和考克兰图书馆在内的数据库中进行文献检索,使用的关键词包括“前列腺癌”“主动监测”“放射治疗”“冷冻疗法”“根治性前列腺切除术”“免疫疗法”“化疗”“雄激素剥夺疗法”“勃起功能障碍”以及“治疗进展”,以收集1966年至2024年6月发表的英文文献。
主动监测(AS)策略显著降低了ED的发生率。诸如放射治疗(RT)、精确勾画技术以及冷冻治疗设备的改进等技术进步均致力于降低ED风险。术中神经监测联合机器人辅助根治性前列腺切除术(RP)在保护海绵体神经及改善术后勃起功能(EF)恢复方面发挥着关键作用。免疫疗法和化疗对ED风险的影响仍需更多临床数据予以阐明。雄激素剥夺疗法(ADT)常作为联合治疗的一部分进行,或通过新型给药方式来减少其副作用。鉴于传统ED治疗方法存在局限性,诸如物理能量疗法、干细胞和富血小板血浆(PRP)疗法、基因和靶向疗法、组织工程与神经移植以及传统中医(TCM)等新兴治疗方法为ED治疗提供了新的解决方案。
随着PCa治疗技术的创新,ED的发生率有所下降,新兴的ED治疗方法有助于PCa患者性功能的恢复。这些进展可能为进一步创新PCa治疗策略奠定基础。